ReviewESMO open2017
Checkpoint inhibitors in the treatment of urological malignancies.
Review in ESMO open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Immune Predictors of Response after BacillusCancers · 2023Review
- Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting.International journal of molecular sciences · 2023Review
- Targeting triple-negative breast cancer: A clinical perspective.Oncology research · 2023Review
- Identification of a Hypoxia-Related Signature for Predicting Prognosis and the Immune Microenvironment in Bladder Cancer.Frontiers in molecular biosciences · 2021Article
- [Influence of immunomodulators on urological imaging].Der Urologe. Ausg. A · 2019Review
- Mitofusin 2 inhibits bladder cancer cell proliferation and invasion via the Wnt/β-catenin pathway.Oncology letters · 2019Article
- Immune checkpoint inhibitors in the treatment of virus-associated cancers.Journal of hematology & oncology · 2019Review
- Relationship between the expression of PD-1/PD-L1 andEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Predicting PD-1/PD-L1 status in bladder cancer withEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Introducing a newESMO open · 2019Article
- Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.Cancer management and research · 2019Article
- How I treat cancer special issue.ESMO open · 2019Article
- Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.Current oncology (Toronto, Ont.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Checkpoint inhibitors are monoclonal antibodies attach to several different receptors on T-cells or tumour cells expressing receptors for cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1) and their ligand (PD-L1). Since 2010, numerous trials on different tumour types have been conducted, which was resulted in these drugs being approved for the treatment of melanoma, lung cancer, Hodgkin's lymphoma and head and neck cancers. Urological cancers, especially urothelial and renal-cell carcinomas, are immunogenic tumours. Since the late 70s, the bacillus Calmette-Gurin (BCG) vaccine has been used for intravesical instillation in non-muscle invasive bladder cancer from the mid-90s up until the discovery of tyrosine kinase inhibitors (TKIs) in 2007, interleukin-2 (IL-2) and interferon alpha (IFNα), which were the standard of care for metastatic renal-cell cancer. Two checkpoint inhibitors are already approved by the Food and Drug Administration: atezolizumab for metastatic urothelial cancer and nivolumab for metastatic renal-cell carcinoma. There are many drugs are in different phases of clinical development. Here we review the current status of checkpoint inhibitors in the treatment of urological tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.